Scientific Reports (Mar 2022)

Neurofunctional and neuroimaging readouts for designing a preclinical stem-cell therapy trial in experimental stroke

  • Chloé Dumot,
  • Chrystelle Po,
  • Lucille Capin,
  • Violaine Hubert,
  • Elodie Ong,
  • Matthieu Chourrout,
  • Radu Bolbos,
  • Camille Amaz,
  • Céline Auxenfans,
  • Emmanuelle Canet-Soulas,
  • Claire Rome,
  • Fabien Chauveau,
  • Marlène Wiart

DOI
https://doi.org/10.1038/s41598-022-08713-z
Journal volume & issue
Vol. 12, no. 1
pp. 1 – 13

Abstract

Read online

Abstract With the aim of designing a preclinical study evaluating an intracerebral cell-based therapy for stroke, an observational study was performed in the rat suture model of ischemic stroke. Objectives were threefold: (i) to characterize neurofunctional and imaging readouts in the first weeks following transient ischemic stroke, according to lesion subtype (hypothalamic, striatal, corticostriatal); (ii) to confirm that intracerebral administration does not negatively impact these readouts; and (iii) to calculate sample sizes for a future therapeutic trial using these readouts as endpoints. Our results suggested that the most relevant endpoints were side bias (staircase test) and axial diffusivity (AD) (diffusion tensor imaging). Hypothalamic-only lesions did not affect those parameters, which were close to normal. Side bias in striatal lesions reached near-normal levels within 2 weeks, while rats with corticostriatal lesions remained impaired until week 14. AD values were decreased at 4 days and increased at 5 weeks post-surgery, with a subtype gradient: hypothalamic < striatal < corticostriatal. Intracerebral administration did not impact these readouts. After sample size calculation (18–147 rats per group according to the endpoint considered), we conclude that a therapeutic trial based on both readouts would be feasible only in the framework of a multicenter trial.